The company announced the collaborations this week in conjunction with the annual American Society for Mass Spectrometry Conference in Atlanta.
Bruker signed a codevelopment and comarketing agreement with PreOmics for sample prep, and a partnership with Genedata for proteomics software.
The facility will be mass spec-focused and comprise a service contract lab for developing protein tests and a CAP- and CLIA-certified lab for offering them.
The company also announced that its board of directors has authorized payment of a quarterly cash dividend of $0.04 per share of its common stock.
The firm said total revenues rose to $461.4 million from $431.7 million in the first quarter of 2018, beating analysts' consensus estimate of $450.1 million.
Roche ran a mock clinical trial in which it used DIA mass spec and targeted proteomics to profile 30 colorectal cancer samples under GCP conditions.
The company posted revenues of $513.9 million for the quarter compared to $530.7 million in Q1 2018, below the average Wall Street estimate of $545.3 million.
The companies will combine their respective technologies to develop mass spectrometry-based proteomics assays for adverse pregnancy outcomes.
A study from the University of Montreal adds to findings indicating the approach can help reduce sample complexity and interferences in quantitative work.
The tool is the latest such package to be released as the field continues to move towards open searching, which could significantly expand breadth of analysis.
The work suggests DIA can be a rapid way to confirm the outcome of CRISPR experiments while looking at the downstream effects of the targeted alterations.
The company is planning a 2020 commercial launch of PNNL's SLIM IMS tech, which could significantly improve the sensitivity and throughput of mass spec assays.
Developed in collaboration with Waters and Labcyte, the platform enables applications including high-throughput drug screening and metabolomic profiling.
However, a shift within the field towards experiments comprising larger numbers of samples and conditions may give DIA an advantage in the future.
In a recent study, researchers combined genomic and proteomic data to identify mutations responsible for a pair of rare monogenic neutrophil diseases.
The study made use of a high-resolution mass spec approach developed by University of Minnesota scientists that allows for untargeted discovery of DNA adducts.
The company reported revenues of $553.6 million, up from $530.5 million in Q4 2017, and beating the average analyst estimate of $544.6 million.
The approach allows researchers to profile the protein complexes present in a sample in much the same way they have the individual peptides and proteins.
The researchers presented new reagents and software for de novo peptide sequencing, an emerging technology with potential in proteomics and biopharma.
Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.